The purpose of the study — to increase the effectiveness of treatment of genital herpes relying on the improved treatment with the use of various forms of the drug Panavir. Material and methods. A study was conducted in 73 patients with recurrent herpes viral infection of the 2nd type, which in the course of treatment with different regimens of Panavir, which differed in the additional introduction of the spray Panavir-Intima. We determined the changes in clinical symptoms and laboratory parameters included complete blood count, coagulogram, C-reactive protein, hepatic enzymes. All statistical studies were conducted in the environment of the STATISTICA 10 package. Results. The sample consisted of patients of reproductive age. The average age was 32.7±2.78 years. In 91.78% of patients the number of relapses was no more than three episodes per year lasting up to 3—7 days without affecting the overall health, and the area of lesion of rashes was small, which corresponds to a mild course of HSV. 8.22% patients had from 4 to 6 episodes with a duration up to 7—14 days with several foci of rash, accompanied by a violation severity. The combined therapy of intravenous administration of Panavir in combination with local use of Panavir intima spray significantly improved the clinical finding, led to normalization laboratory parameters when compared only with systemic therapy Panavir, which allows to use this scheme for recurrent HSV up to 3 times a year as a treatment method with the recommendation of course of rectal suppositories Panavir once every 6 months. Conclusion. The usage of Panavir as systemic and local therapy followed by anti-ralapse treatment reduces the incidence of genital herpes recurrence by 19.23%.